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Abstract
Natural products represent a significant reservoir of unexplored chemical diversity for early-stage drug discovery. The
identification of lead compounds of natural origin would benefit from therapeutically relevant bioassays capable of
facilitating the isolation of bioactive molecules from multi-constituent extracts. Towards this end, we developed an in vivo
bioassay-guided isolation approach for natural product discovery that combines bioactivity screening in zebrafish embryos
with rapid fractionation by analytical thin-layer chromatography (TLC) and initial structural elucidation by high-resolution
electrospray mass spectrometry (HRESIMS). Bioactivity screening of East African medicinal plant extracts using fli-1:EGFP
transgenic zebrafish embryos identified Oxygonum sinuatum and Plectranthus barbatus as inhibiting vascular development.
Zebrafish bioassay-guided fractionation identified the active components of these plants as emodin, an inhibitor of the
protein kinase CK2, and coleon A lactone, a rare abietane diterpenoid with no previously described bioactivity. Both emodin
and coleon A lactone inhibited mammalian endothelial cell proliferation, migration, and tube formation in vitro, as well as
angiogenesis in the chick chorioallantoic membrane (CAM) assay. These results suggest that the combination of zebrafish
bioassays with analytical chromatography methods is an effective strategy for the rapid identification of bioactive natural
products.
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Introduction
Small molecules from natural sources are recognized as evolved,
privileged structures with greater likelihood than many synthetic
compounds to exhibit specific bioactivities [1]. For example, 73%
of cancer therapeutics approved to date are either natural products
or derivatives thereof [2]. Nevertheless, the use of natural products
in drug discovery has significantly declined in the past two
decades, due in part to persisting difficulties in the systematic
isolation and synthesis of such molecules [3]. One promising
strategy to better exploit the therapeutic potential of natural
products could be the use of more biomedically relevant assays –
ideally in vivo models – for the screening and bioactivity-guided
fractionation of plant, fungal and microbial extracts.
Many currently known bioactive natural products were
originally identified using in vitro assays (e.g. cytotoxicity in tumor
cells) for their activity-guided isolation from extracts. The
biological activity of many other natural products was determined
only after their initial isolation on the basis of physical
characteristics (e.g., preparative chromatography followed by mass
spectrometry and NMR spectroscopy analysis). Because of the low
throughput of conventional in vivo models such as mice and rats, in
addition to the relatively large amounts of compound required for
testing in these systems, in vivo assay-guided fractionation is
currently not a widely-used approach for the discovery of drug-like
natural products.
Novel opportunities for in vivo natural product discovery have
arisen through the recent emergence of zebrafish as an effective
model system for the identification of disease-relevant genes and
bioactive small molecules [4]. Large-scale genetic screens in zebrafish
carried out since the early 1990s have led to the identification of
therapeutically relevant genes in several indication areas, including
cardiovascular, neurological, gastrointestinal, musculoskeletal, and
metabolic disorders [5,6,7,8]. In addition, small-molecule screens
carried out in zebrafish within the past decade have confirmed the
ability of this model system to identify bioactive compounds in a
target-independent manner, thereby enabling the discovery of novel
mechanisms of action [9,10,11,12,13].
The primary advantages of zebrafish for drug discovery include
their high genetic, physiologic, and pharmacologic similarity with
humans, as well as the small size, optical transparency, rapid
development, and large numbers of their embryos and larvae,
which are the primary system for experimental analysis. Because
of their small size (1 to 5 mm), zebrafish embryos and larvae are
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96-well plates, but even 384-well plates are possible), thereby
requiring only microgram amounts of each extract, fraction, or
compound to be tested. Because of the high fecundity of zebrafish,
large numbers of embryos and larvae can be produced and
analyzed in a more cost-effective manner than, for example, mice
and rats. Combined, these features define zebrafish as an ideal in
vivo model for the systematic identification of bioactive natural
products with therapeutic potential [4].
For an initial evaluation of zebrafish as a platform for natural
product discovery, we opted to identify novel inhibitors of
angiogenesis. Despite the recent regulatory approval of recombi-
nant antibodies and small molecules targeting the vascular
endothelial growth factor (VEGF) pathway, the clinical efficacy
of these therapies for various cancers is limited [14]. Also, despite
the large number of compounds targeting this pathway [15], many
of these have shown limited or insufficient efficacy in clinical trials,
or are associated with toxicities such as arterial thromboembolic
events [16]. For these reasons, there is still a need for novel anti-
angiogenic compounds with different mechanisms of action, some
of which might be suitable for use in combinatorial therapy
strategies [17].
Numerous in vivo and in vitro assays have been developed since the
1970s for the evaluation of anti-angiogenic molecules [18], yet
because of various disadvantages (low throughput, high cost, and
the requirement for larger compound amounts in the case of in vivo
assays, and limited predictive value in the case of in vitro assays),
these are not ideal as front-line assays for natural product discovery
(i.e. for high-throughput screening and rapid bioassay-guided
fractionation). Zebrafish, however, offer an interesting combination
of (1) being an in vivo model and (2) enabling high-throughput, low-
volume screening. Within the past decade, zebrafish embryos have
become well-established as an in vivo model for the analysis of
angiogenesis and vascular development [9,19,20,21,22,23]. To test
the suitability of zebrafish as an in vivo frontline assay for the
bioassay-guided fractionation of complex natural extracts, we
therefore combined an embryonic zebrafish angiogenesis assay
with analytical chromatography methods, with the goal of rapidly
isolating phytochemicals from medicinal plant extracts capable of
inhibiting vascular outgrowth in this assay.
Results and Discussion
We chose an angiogenesis assay based on the evaluation of
intersegmental vessel (ISV) outgrowth in fli-1:EGFP transgenic
embryos [19], which exhibit vasculature-specific expression of
enhanced green fluorescent protein (EGFP) in the trunk and tail
during embryonic and larval development (Figs. 1a, b). With
respect to natural product research, fli-1:EGFP zebrafish have
been used to characterize the angiogenic activity of Angelica sinensis
(dong quai) [24], as well as the anti-angiogenic activity of
solenopsin, an alkaloid isolated from Solenopsis invicta (fire ants)
[25]. Similar transgenic lines, with fluorescent reporter proteins
expressed under the control of the endothelial cell-specific flk-1/
VEGFR2 promoter, have recently enabled an ENU mutagenesis
screen to identify genetic determinants of vascular development
[26] and a small-molecule screen to identify novel angiogenesis
inhibitors [27].
Figure 1. Crude methanolic extracts and isolated compounds inhibit vascular outgrowth in fli-1:EGFP transgenic embryos. All
embryos are 40 hpf, with anterior to the left, scale bar = 100 mm. a, b, DMSO-treated control; c, embryo treated with 200 mg/ml O. sinuatum extract;
d, embryo treated with 10 mg/ml P. barbatus extract; e, embryo treated with 8 mM emodin; f, embryo treated with 2 mM coleon AL.
doi:10.1371/journal.pone.0014694.g001
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discovery, we screened crude methanolic extracts from over 80
East African medicinal plants. Two extracts, from Oxygonum
sinuatum (Meisn.) Dammer (Polygonaceae) and Plectranthus barbatus
Andrews (Lamiaceae), inhibited ISV outgrowth in fli-1:EGFP
embryos in a dose-dependent manner (Figs. 1c, d and 2a, b).
In terms of known bioactivities for these plants, O. sinuatum has
been documented as an ethnobotanical treatment in Kenya for
several unrelated disorders [28]. No phytochemical analysis of this
plant has been reported to date. P. barbatus (previously also known
as Coleus forskohlii Briq.) is widely used in traditional medicine in
Africa and Latin American to treat a range of human ailments
[29]. This species is also well-known as the primary source of
forskolin, a labdane diterpenoid and activator of cAMP signaling
[30,31]. Intruigingly, although forskolin has been shown to inhibit
angiogenesis in the chick chorioallantoic membrane assay [32] and
in vitro [33], it is also known to upregulate VEGF expression [34],
making its overall effect on angiogenesis in vivo difficult to predict.
We determined that forskolin does not inhibit angiogenesis in
zebrafish (data not shown) and since it is isolated from P. barbatus
roots (an extract from leaves being the subject of this analysis), we
concluded that the anti-angiogenic activity seen in zebrafish
embryos for the P. barbatus extract is likely due to the bioactivity of
another compound.
We next sought to isolate from O. sinuatum and P. barbatus extracts
the principle components responsible for their anti-angiogenic
effects. Both crude methanolic extracts were fractionated via thin-
layer chromatography (TLC), using toluene/ethyl formate/formic
acid (5:4:1) as the solvent. A single analytical-scale TLC plate
(20620 cm) was used to separate 10 mg of each extract, and was
subsequently divided into 10-15 horizontal strips based on the
presence of UV254 -absorbing and UV365-emitting components
(Figs. 3 a, b). The silica was removed from these strips and extracted
with methanol, after which the eluted constituents were subjected to
bioactivity analysis in zebrafish, followed by high-resolution
electrospray ionization mass spectroscopy (HRESIMS) for those
exhibiting anti-angiogenic activity. For both O. sinuatum and P.
barbatus, single TLC fractions were identified in this manner which
phenocopied the anti-angiogenic activity shown by the crude
extracts.
O. sinuatum yielded a single bioactive compound whose
molecular formula was determined to be C15H10O5 based on the
deprotonated molecular ion at m/z 269.0457 identified by
HRESIMS analysis (negative mode), suggesting 6-methyl-1,3,8-
trihydroxyanthraquinone (emodin) – a known product of several
other Polygonaceae species. Emodin has recently been reported as
an inhibitor of angiogenesis in vitro [35] and in vivo [36], and has
beenshown to be an inhibitorof the protein kinases Lck[37], HER-
2 [38], and CK2 [39]. More recently, emodin was shown to inhibit
angiogenesis in vitro at least in part by restricting the phosphor-
ylation of VEGFR2 [40]. In addition; CK2 has been found to
directly phosphorylate Akt [41], one of several downstream
Figure 2. Crude methanolic extracts and isolated compounds exhibit concentration-dependent effects on vascular outgrowth in
zebrafish embryos. Relative vascular outgrowth scores are shown (see Materials & Methods). a, O. sinuatum crude extract; b, P. barbatus crude
extract; c, emodin; d, coleon AL.
doi:10.1371/journal.pone.0014694.g002
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to be essential for nuclear retention of FOXO1, an important
cytoplasmic inhibitor of angiogenesis [42]. Semi-synthetic emodin
revealed an MS spectrum identical to the bioactive compound
isolated from O. sinuatum (data not shown) and, importantly,
phenocopiedboth thiscompoundandthecrudeextract(Fig.1e,2c),
thereby confirming emodin as the primary constituent responsible
for this plant’s bioactivity. Furthermore, emodin and other
anthraquinones synthesized by Rheum species (rhubarb root, or
Dahuang) have recently also been shown to inhibit vascular
outgrowth in zebrafish using a histochemical assay to visualize
blood vessels [43].
P. barbatus yielded a bioactive molecule with an apparent Mw of
355.1190 based on HRESIMS analysis and the predicted
molecular formula C20H19O6, suggesting coleon A lactone, a
known product [44] of another Lamiaceae species but with no
previously described bioactivity. Following isolation by prepara-
tive-scale chromatography, the identity of coleon A lactone
(hereinafter referred to as coleon AL) was confirmed by NMR
(Table 1).
Zebrafish have only recently been utilized for the systematic
identification of bioactive small molecules [12], so the predictive
power of zebrafish assays for drug discovery will only become clear
as molecules found using this platform are advanced into the
clinic. In any case, to further evaluate the therapeutic potential of
natural products identified using embryonic or larval zebrafish
models, bioactive compounds should subsequently be validated
using a series of additional in vitro and in vivo assays. To this end, in
vitro anti-angiogenesis assays were carried out to further charac-
terize the anti-angiogenic activity of the bioactive natural products
isolated in this study, revealing both emodin and coleon AL
to inhibit the proliferation, migration and tube formation of
mammalian endothelial cells (Table 2, Fig. 4, 5). In addition, both
compounds inhibited blood vessel formation in the chick
chorioallantoic membrane (CAM) assay (Fig. 6). Emodin and
coleon AL inhibited the proliferation of mouse aortic endothelial
cells (MAECs) with an IC50 similar to that of the vascular
endothelial growth factor (VEGF) receptor inhibitor SU5416, a
synthetic indoline derivative [45], and inhibited the proliferation
of bovine aortic endothelial cells (BAECs) with an IC50 similar to
that of the PI3K inhibitors wortmannin, a fungal furanosteroid
[46], and LY294002, a synthetic chromone derivative [47]. In the
CAM assay, we determined the anti-angiogenic activity of emodin
and coleon AL to be similar to that of SU5416.
As a next step, in vivo angiogenesis assays should be carried out
for these compounds in mammalian models, including mouse
tumor assays [18]. Additional in vitro assays should also be
performed to determine the activity of anti-angiogenic compounds
under hypoxic conditions, an important condition for possible
application in antitumor therapy [48].
Zebrafish were first proposed as a model for in vivo drug
discovery in 1957 by Jones and Huffmann of the Oklahoma
Research Foundation [49], and soon thereafter were used for the
first time to analyze the bioactivities of natural products [50]. Only
more recently, however, have zebrafish been widely used for the
function-based identification of disease-relevant genes and bioac-
tive compounds [12]. An important advantage of using zebrafish
embryos and larvae for the identification of bioactive molecules is
that they are living organisms, thereby enabling the rapid in vivo
evaluation of compounds not only in terms of their pharmacolog-
ical activity but also of their possible toxicity (particularly cardio-,
neuro-, and hepatotoxicity) early in the drug discovery process
[51,52]. Within the past decade, zebrafish have furthermore
emerged as a powerful model for chemical genetics, both with
respect to the in vivo dissection of signaling pathways [20,53] and to
the elucidation of the mechanism of action of bioactive natural
Table 1. NMR spectroscopy analysis confirms identity of coleon AL.
a.
1H NMR data in CDCl3
Ref. 44 experimental
1.31 (6H, d, J=7.1 Hz) CH3-16/17 1.306 (6H, d, J=7.0 Hz)
1.65 (3H, s) CH3-10 1.662 (3H, s)
2.69 (3H, s) CH3-14 1.689 (3H, s)
2.83 (2H, d, J=6.0 Hz) H-11A
H-11B
2.811 (1H, dd,
2J=14.0 Hz,
3J=7.5Hz)
2.868 (1H, dd,
2J=14.0 Hz,
3J=7.3Hz)
3.38 (1H, pent, J=7.1 Hz) H-15 3.378 (1H, sept, J=7.0 Hz)
4.90 – 5.60 (3H, m) H-13A
H-13B
H-12
4.955 (1H, dd, J=9.9 Hz, J=1.1 Hz)
5.054 (1H, dd, J=17.0 Hz, J=1.1 Hz)
5.326 (1H, ddt, J=17.0/9.9/7.4 Hz)
7.96 (1H, s) 9-OH 8.01 (1H, s)
13.25 (1H, s) 6-OH 13.35 (1H, s)
b.
13C NMR data in CDCl3
190.8 (C-8), 181.3 (C-5), 177.7 (C-2), 154.1 (C-6), 146.9 (C-9a), 146.1 (C-9), 135.5 (C-3a), 132.0 (C-4a), 130.8 (C-12), 126.4 (C-7), 122.5 (C-4), 120.2 (C-13), 117.1 (C-8a), 50.0 (C-
3), 41.6 (C-11), 23.9 (C-15), 22.9 (C-10), 19.7 (C-16/17), 17.3 (C-14) ppm.
a, Comparison of 1H-NMR chemical shift assignments from Ref. 44 and our experimental data, with more resolution for protons H-11A, 11B, 13A, 13B and 12; b, 13C
NMR experimental chemical shift assignments, with 3 carbonyl peaks at 177–190 ppm, and olefinic peaks at 117–154 ppm corresponding to the aromatic fused-ring
moeities.
doi:10.1371/journal.pone.0014694.t001
Figure 3. TLC fractionation and HRESIMS analysis identify emodin and coleon AL as bioactive constituents. Thin-layer chromatograms,
HRESIMS spectra, and predicted structures of isolated, bioactive compounds. a, O. sinuatum;b ,P. barbatus.
doi:10.1371/journal.pone.0014694.g003
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recent report describes the application of a histochemical assay in
zebrafish to guide the isolation of anti-angiogenic terpenoids from
Tripterygium wilfordii, an anti-inflammatory Chinese medicinal
plant, using preparative chromatography methods [56].
Here, we demonstrate the utility of zebrafish bioassay-guided
fractionation by analytical chromatography techniques, and
further establish zebrafish as an in vivo platform for the discovery
of bioactive natural products. Based on these initial results, it
appears possible that zebrafish can help address a critical
bottleneck in natural product discovery by enabling the rapid, in
vivo and microgram-scale bioactivity analysis, bioassay-guided
fractionation, and dereplication of complex natural extracts. While
data described here were obtained using zebrafish bioassay-guided
TLC fractionation, additional advantages for accelerating natural
product discovery will be realized through the combination of
zebrafish bioassays with more advanced HPLC techniques – in
particular, those enabling microfractionation [57,58]. With a wide
array of biomedically relevant assays now established in zebrafish
[4], the advantages of this in vivo system for natural product
discovery should facilitate the systematic identification of a new
generation of bioactive natural products with potential utility in
drug discovery.
Materials and Methods
Zebrafish
The fli-1:EGFP transgenic line [19] was obtained from the
Zebrafish International Resource Center at the University of
Oregon (Eugene, Oregon, USA). Zebrafish husbandry, embryo
collection, and embryo and larvae maintenance were performed
as described earlier [59,60]. Zebrafish assays were standardly
performed in 24-well microtiter plates using 10 embryos per well
in 1 ml of 0.36 Danieau’s medium (17 mM NaCl, 2 mM KCl,
0.12 mM MgSO4, 1.8 mM Ca(NO3)2 and 1.5 mM HEPES,
pH 7.6). Embryos were exposed to extracts and compounds at
16 hours post-fertilization (hpf) – approximately 8 hours prior to
the initiation of intersegmental vessel (ISV) outgrowth – and
scored for relative vascular outgrowth at 40 hpf. Extracts and
compounds were solubilized in dimethyl sulfoxide (DMSO, Agros
Organics, Geel, Belgium), and were added to the medium up to a
maximum DMSO concentration of 1%. The extent of outgrowth
of intersegmental vessels (ISVs) was determined using a scoring
method that takes into account both the approximate number of
outgrowing vessels (100, 75, 50, 25, or 0%) and the average degree
to which these vessels have extended into the trunk from the dorsal
aorta/posterior cardinal vein (DA/PCV) (100, 75, 50, 25, or 0%).
These two values are multiplied to give the relative vascular
outgrowth (RVO) score.
Figure 4. Emodin and coleon AL inhibit endothelial cell migration in vitro. a, control (immediate); b, control; c, 30 mM emodin; d, 30 mM
coleon AL.
doi:10.1371/journal.pone.0014694.g004
Table 2. Emodin and coleon AL inhibit endothelial cell
proliferation in vitro.
IC50 (mM)
MAEC BAEC
emodin 32611 3969
coleon AL 30653 1 613
wortmannin 55652 9 612
LY294002 7623 61
SU5416 29628 62
IC50 values (6 SD) for emodin and coleon A lactone are shown for the inhibition
of proliferation of both bovine aortic endothelial cells (BAEC) and mouse aortic
endothelial cells (MAEC). For comparison, effects of 3 other anti-angiogenic
compounds are shown (wortmannin, LY294002, and SU5416).
doi:10.1371/journal.pone.0014694.t002
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Plant samples were collected from different locations in
Tanzania and their respective voucher specimens deposited at
the Department of Pharmacognosy, Faculty of Pharmacy of the
Muhimbili University of Health and Allied Sciences (MUHAS),
Dar es Salaam, Tanzania. For each plant sample, plant materials
were dried at room temperature and ground. The dry, powdery
plant samples were exhaustively extracted with methanol by
maceration. Dry methanolic extracts were obtained after removing
the solvent by evaporation under reduced pressure. Prior to
testing, aliquots of each dry methanolic extract were suspended in
100% DMSO; these stock solutions were then kept at 220 uC.
Compounds
Semi-synthetic emodin was obtained from Janssen Chimica
(Geel, Belgium). SU5416 and wortmannin were obtained from
Sigma-Alrich (Bornem, Belgium) and LY294002 was obtained
from Cayman Chemical (Talinn, Estonia). Coleon A lactone
(coleon AL) was isolated from leaves of Plectranthus barbatus
collected in Handeni, Tanga Region, Tanzania. Leaves were
dried at ambient temperature under sunlight, homogenized, and
extracted 3 times with chloroform (1 l chloroform per 100 g
leaves). This chloroform extract was concentrated 100:1 on a
rotary evaporator and subjected to chromatographic separation on
a LaFlash chromatography apparatus from VWR (West Chester,
Pennsylvania, USA) using VWR SuperVarioFlash silica cartridges
(30 g, Si60, pore size 15-40 mM), with chloroform:acetic acid
200:1 as the solvent. Coleon AL was isolated as the second major
peak showing absorbance at 254 nm.
Thin-layer chromatography
TLC plates were obtained from Macherey-Nagel (Du ¨ren,
Germany). For the experiments described here, 20620 cm
aluminum plates coated with TLC silica gel 60 (layer thickness,
0.2 mm) containing a UV254 fluorescence indicator were used
(ALUGRAM SIL G/UV254, Machery-Nagel product number
818133). Plates were loaded manually, using a finely tapered
micropipette tip, with 10 mg of crude extract (50 mg/ml in
methanol), dried for 15 seconds with a hair dryer at low heat, and
placed in an enclosed, upright 25625610 cm glass chamber
containing 100 ml toluene/ethyl formate/formic acid 5:4:1 (pre-
equilibrated for at least 15 minutes, and with 3 vertical faces
covered with solvent-saturated filter paper).
High-resolution electrospray ionization mass
spectrometry
Electrospray ionization (ESI) mass spectra were recorded in positive
and negative mode on an orthogonal acceleration quadrupole time-of-
flight mass spectrometer (Q-Tof 2, Micromass, Manchester, UK). The
electrospray needle voltage was set to 3000 V or 22850 V for the
positive and negative mode respectively. Fragment ion spectra were
Figure 6. Emodin and coleon AL inhibit angiogenesis in the
chick chorioallantoic membrane (CAM) assay. a, negative control;
b, positive control (50 nmol SU5416); c, 50 nmol emodin; d, 50 nmol
coleon AL.
doi:10.1371/journal.pone.0014694.g006
Figure 5. Emodin and coleon AL inhibit endothelial tube formation in vitro. a, DMSO-treated control; b, 10 mM emodin; c, 10 mM coleon AL.
doi:10.1371/journal.pone.0014694.g005
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collisional activation with argon gas in the collision cell. Accurate mass
measurements were performed at a resolution of 9000 using the
protonated leucine-enkephaline (YGGFL) ion as lock mass.
NMR spectroscopy
1H and
13C NMR spectra were recorded on a Bruker (Fa ¨llanden,
Switzerland) Avance II 500 spectrometer operating at
500.130 MHz for
1H and at 125.758 MHz for
13C, and using a
gradient-equipped inverse 5 mmtriple probewith p/2 pulsesof 6.5,
and 14.5 ms respectively. The standard Bruker Topspin 2.1 software
under Windows XP was used throughout. All experiments were
performed at 22 uC in deuterochloroform solution with the solvent
peakasinternal standard setat7.27 ppm(
1H)or77.0(
13C)vs.TMS
respectively. First-order analysis was applied throughout, and first-
order multiplets or apparent first-order multiplets were denoted as
follows: s = singlet, d = doublet, dd = double doublet, t = triplet.
J-values were extracted directly from the splittings in the spectrum,
and are not optimised. Spectral assignments were based not only on
the usual chemical shift rules and coupling patterns, but especially
on routine 2D-correlations such as COSY45- (homonuclear H,H J-
correlations), GHSQC- (single bond C,H
1J-correlations) and
GHMBC-experiments (multiple bond C,H
3J-correlations). The
data for coleon AL are summarized in Fig. 4 and compared with
previously reported values [44].
Imaging
Zebrafish were screened for GFP fluorescence using an Axiovert
40 CFL microscope from Zeiss (Oberkochen, Germany) equipped
with an MBQ 52 AC fluorescence lamp from LEJ (Jena,
Germany). Micrographs of zebrafish embryos were taken on a
Stemi 2000 stereo microscope from Zeiss equipped with a DP200
CMOS digital camera and using DpxView Pro EE EF software,
both from Deltapix (Maalov, Denmark). Confocal fluorescence
micrographs of zebrafish embryos were acquired using a Nikon
A1R confocal unit mounted on a Ti2000 inverted microscope
(Nikon, Tokyo, Japan). The microscope was equipped with 46
(0.2 N.A.) and 106(0.45 N.A.) objective lenses, and fluorescence
was revealed using a 488 nm laser line (CVI Melles Griot,
Albuquerque, NM, USA). For imaging, zebrafish embryos were
anesthetized using 0.1 mg/ml ethyl 3-aminobenzoate methane-
sulfonate (Sigma) in 0.36Danieau’s solution.
Cell cultures
Mouse aortic endothelial cells (MAEC) and bovine aortic
endothelial cells (BAEC) were kindly provided by Prof. M. Presta
(Brescia, Italy). The cells were grown in Dulbecco’s modified
minimum essential medium (DMEM, Life Technologies, Rock-
ville, MD, USA) supplemented with 10 mM Hepes (Life
Technologies) and 10% fetal calf serum (FCS, Harlan Sera-Lab,
Loughborough, UK).
Cell proliferation assays
Cells (MAEC or BAEC) were seeded in 48-well plates at 10,000
cells per cm
2. After 16 h, the cells were incubated in fresh medium
in the presence of different concentrations of the test compounds
(i.e. 100 - 20 - 4 - 1 - 0.2 mM). On day 5, cells were trypsinized and
counted by a Coulter counter (Analis, Belgium). The compound
concentration that inhibits cell growth by 50 % (i.e. IC50) was
calculated based on cell counts in control cultures.
Cell migration assay
Wounds were created in confluent MAE cell monolayers with a
1.0-mm wide micropipette tip. Then, cells were incubated in fresh
mediumcontaining 10%FCSinthepresenceof the testcompounds.
After 8 h, the wounds were photographed, and endothelial cells
invading the wound were quantified by computerized analysis of the
digitalized images.
Tube formation assay
Wells of a 96-well plate were coated with 60 ml matrigel
(10 mg/ml, BD Biosciences, Heidelberg, Germany) at 4 uC. After
gelatinization at 37 uC during 30 min, BAEC (60,000 cells) were
seeded on top of the matrigel in 200 ml DMEM containing 1%
FCS and the test compounds. After 6 hours of incubation, the
cell structures were photographed at 1006magnification. Tube
formation was quantified by counting the number of branching
points.
Chorioallantoic membrane (CAM) assay
The in vivo CAM angiogenesis model was performed as described
with slight modifications [61]. Fertilized chicken eggs were
incubated for 3 days at 37 uC when 3 ml of albumen was removed
(to detach the shell from the developing CAM) and a window was
opened on the eggshell exposing the CAM. The window was
covered with cellophane tape and the eggs were returned to the
incubator until day 9 when the compounds were applied. The
compounds were placed on sterile plastic discs (Ø 8 mm), which
were allowed to dry under sterile conditions. A solution of cortisone
acetate (100 mg/disc, Sigma-Aldrich, St. Louis, MO, USA) was
added to all discs in order to prevent an inflammatory response. A
loaded and dried control disc was placed on the CAM
approximately 1 cm away from the disc containing the test
compound(s). Next, the windows were covered and the eggs further
incubated until day 11 when the area around the discs was cut-off
and photographed. Then, 2 concentric circles were positioned on
the digitalized pictures and all vessels intersecting these circles were
counted. A two-tailedpaired Student’s t-test wasperformed to assess
the significance of the obtained results.
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